Methods and materials for treating a stroke
US-2024197832-A1 · Jun 20, 2024 · US
US2017028037A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017028037-A1 |
| Application number | US-201615293077-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 13, 2016 |
| Priority date | Dec 24, 2008 |
| Publication date | Feb 2, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Reduced-pressure treatment systems and methods are disclosed that employ debridement mechanisms to remove unwanted tissue. In one instance, a reduced-pressure treatment system for treating a tissue site on a patient includes a manifold member for distributing reduced pressure to the tissue site, a support member for disposing proximate the tissue site and the manifold, and a debridement mechanism coupled to the support member. The debridement mechanism is for debriding the tissue site. The system further includes a sealing drape for placing over the tissue site and manifold member. The sealing drape is operable to form a fluid seal over the tissue site and manifold member. The system also includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing drape. The system may further include a chemical-debridement subsystem. Other systems, manifolds, and methods are disclosed.
Opening claim text (preview).
1 .- 19 . (canceled) 20 . A method for treating a tissue site on a patient, the method comprising: placing a manifold member adapted to contract in response to application of reduce pressure proximate the tissue site, wherein the manifold member comprises a support member and a debridement arm having a proximal end and a distal end, the proximal end operatively coupled to the support member and the distal end having a face including an edge to debride the tissue site in response to contraction of the manifold member when induced by the application of reduced pressure; disposing a sealing drape over the manifold member and the patient's epidermis; forming a fluid seal between the sealing drape and the patient's epidermis to form a fluid seal over the tissue site and the manifold member; and providing a reduced pressure to the manifold member whereby the debridement arm is deformable to drive the edge of the face against the tissue site in response to contraction of the manifold member. 21 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site. 22 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site and wherein the debriding chemical is one or more enzymes isolated from insect larvae. 23 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site, wherein the debriding chemical is one or more enzymes isolated from insect larvae, and wherein the larvae are larvae from Lucilia sericata. 24 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site, and wherein the debriding chemical is one or more synthetic analogues of one or more enzymes isolated from insect larvae. 25 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site, wherein the debriding chemical is one or more synthetic analogues of one or more enzymes isolated from insect larvae, and wherein the larvae are larvae from Lucilia sericata. 26 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site, wherein the debriding chemical is one or more enzymes isolated from insect larvae, and wherein the debriding chemical is a chemical selected from the group consisting of: collagenase, ficin, pepsin, trypsin, chymotrypsin, papain and elastase. 27 . The method of claim 20 , further comprising introducing a debriding chemical to the tissue site, and flushing the tissue site. 28 . (canceled) 29 . (canceled) 30 . (canceled) 31 . (canceled) 32 .- 36 . (canceled) 37 . The method of claim 20 , wherein the debridement arm deforms in response to a compressive force of the manifold member contracting and causing the distal end of the debridement arm to move from a neutral position to a compressed position, whereby the edge of the face is driven against the undesired tissue. 38 . The system of claim 37 , wherein the debridement arm forms a first angle with respect to the manifold member when in the neutral position and a second angle with respect to the manifold member when in the compressed position, and wherein the first angle is greater than the second angle.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title
for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title
Assembling or joining · CPC title
Drainage appliance for wounds or the like {, i.e. wound drains, implanted drains} ({negative pressure wound therapy devices A61M1/90;} implements for holding wound open A61B17/02 {; middle ear drainage A61F11/202}) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.